Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized X...
Saved in:
| Published in | iScience Vol. 26; no. 11; p. 108147 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
17.11.2023
Elsevier BV Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate in vitro. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1.
[Display omitted]
•The antigenicity of XBB.1.9.1 is similar to that of XBB.1.5•XBB.1.9.1 remains susceptible to antiviral drugs•The replicative ability of XBB.1.9.1 is comparable to that of XBB.1.5
Virology; Clinical microbiology |
|---|---|
| AbstractList | The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate
in vitro
. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1.
•
The antigenicity of XBB.1.9.1 is similar to that of XBB.1.5
•
XBB.1.9.1 remains susceptible to antiviral drugs
•
The replicative ability of XBB.1.9.1 is comparable to that of XBB.1.5
Virology; Clinical microbiology The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate in vitro. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1.The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate in vitro. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1. The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate . Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1. The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate in vitro. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1. The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate in vitro. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1. [Display omitted] •The antigenicity of XBB.1.9.1 is similar to that of XBB.1.5•XBB.1.9.1 remains susceptible to antiviral drugs•The replicative ability of XBB.1.9.1 is comparable to that of XBB.1.5 Virology; Clinical microbiology |
| ArticleNumber | 108147 |
| Author | Koga, Michiko Uraki, Ryuta Suzuki, Tadaki Yotsuyanagi, Hiroshi Adachi, Eisuke Watanabe, Shinji Iwatsuki-Horimoto, Kiyoko Saito, Makoto Yamayoshi, Seiya Kiso, Maki Kikuchi, Tetsuhiro Tsutsumi, Takeya Kawaoka, Yoshihiro Sakai-Tagawa, Yuko Yamamoto, Shinya Fukushi, Shuetsu Imai, Masaki Ito, Mutsumi Otani, Amato Maeda, Ken |
| Author_xml | – sequence: 1 givenname: Ryuta surname: Uraki fullname: Uraki, Ryuta organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 2 givenname: Mutsumi surname: Ito fullname: Ito, Mutsumi organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 3 givenname: Maki surname: Kiso fullname: Kiso, Maki organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 4 givenname: Seiya surname: Yamayoshi fullname: Yamayoshi, Seiya organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 5 givenname: Kiyoko surname: Iwatsuki-Horimoto fullname: Iwatsuki-Horimoto, Kiyoko organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 6 givenname: Yuko surname: Sakai-Tagawa fullname: Sakai-Tagawa, Yuko organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 7 givenname: Masaki surname: Imai fullname: Imai, Masaki organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 8 givenname: Michiko surname: Koga fullname: Koga, Michiko organization: Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 9 givenname: Shinya surname: Yamamoto fullname: Yamamoto, Shinya organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 10 givenname: Eisuke surname: Adachi fullname: Adachi, Eisuke organization: Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 11 givenname: Makoto surname: Saito fullname: Saito, Makoto organization: Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 12 givenname: Takeya surname: Tsutsumi fullname: Tsutsumi, Takeya organization: Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 13 givenname: Amato surname: Otani fullname: Otani, Amato organization: Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 14 givenname: Shuetsu surname: Fukushi fullname: Fukushi, Shuetsu organization: National Institute of Infectious Diseases, Tokyo, Japan – sequence: 15 givenname: Shinji surname: Watanabe fullname: Watanabe, Shinji organization: National Institute of Infectious Diseases, Tokyo, Japan – sequence: 16 givenname: Tadaki surname: Suzuki fullname: Suzuki, Tadaki organization: National Institute of Infectious Diseases, Tokyo, Japan – sequence: 17 givenname: Tetsuhiro surname: Kikuchi fullname: Kikuchi, Tetsuhiro organization: Clinic of Nihon Sumo Kyokai, Tokyo, Japan – sequence: 18 givenname: Hiroshi surname: Yotsuyanagi fullname: Yotsuyanagi, Hiroshi organization: Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, University of Tokyo, Tokyo, Japan – sequence: 19 givenname: Ken surname: Maeda fullname: Maeda, Ken organization: National Institute of Infectious Diseases, Tokyo, Japan – sequence: 20 givenname: Yoshihiro orcidid: 0000-0001-5061-8296 surname: Kawaoka fullname: Kawaoka, Yoshihiro email: yoshihiro.kawaoka@wisc.edu organization: Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan |
| BackLink | https://cir.nii.ac.jp/crid/1872272492644395648$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/37876803$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1r3DAUFCWlSdP8gR6KDz3ksq6-bElQKEnoRyDQQ3PoTcjy81aLV9pK3oX8-z7XSUl6CAhJPM2beWjmNTmKKQIhbxmtGWXth00dig81p1xgQTOpXpAT3mizolTyo0f3Y3JWyoZSynFJ074ix0Jp1WoqTsiPiziFQ8hurGAYgnf-rnJrF2KZKhf7KsNuxCpioBrCFKGUKg34VP28vKxZbWpW-TFExIxVKGl0E7whLwc3Fji7P0_J7ZfPt1ffVjffv15fXdysfCO4WkHbdTiG6B1OKWjHWykY5yBbYTrTUW24GrhyvRlaoFr1wBunaNcr3iFUnJLrhbZPbmN3OWxdvrPJBfu3kPLaujwFP4LtvDegew-0NZJS51pkdVqKhgrPG4lcnxau3b7bAgLjhF_yhPTpSwy_7DodLKONoVooZDi_Z8jp9x7KZLdoEIyji5D2xXKtmWJCSo7Qd4_F_qk8uIIAvQB8TqVkGKwPE3qQZu0woqidM2A3ds6AnTNglwxgK_-v9YH92ab3S1MMAaXmnWnFucK4oCtSmKaVGmEfFxigqYcA2SIRRA99yOAn_PbwnMofu1vSUg |
| CitedBy_id | crossref_primary_10_1021_acs_oprd_3c00494 crossref_primary_10_1016_j_isci_2024_110729 crossref_primary_10_3390_ijms25158155 crossref_primary_10_1128_cmr_00119_23 crossref_primary_10_1128_jcm_00042_24 |
| Cites_doi | 10.1016/S1473-3099(23)00070-1 10.1056/NEJMc2207519 10.1016/S2666-5247(23)00100-3 10.1016/j.celrep.2023.112443 10.3389/fmicb.2018.03026 10.1056/NEJMc2214302 10.1002/cpim.116 10.1016/S1473-3099(23)00010-5 10.1073/pnas.2106535118 10.1016/S1473-3099(23)00051-8 10.1073/pnas.2002589117 10.1056/NEJMc2119407 |
| ContentType | Journal Article |
| Copyright | 2023 The Author(s) 2023 The Author(s). 2023 The Author(s) 2023 |
| Copyright_xml | – notice: 2023 The Author(s) – notice: 2023 The Author(s). – notice: 2023 The Author(s) 2023 |
| DBID | 6I. AAFTH RYH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.isci.2023.108147 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CiNii Complete CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2589-0042 |
| ExternalDocumentID | oai_doaj_org_article_bcc9e8dce069400aa6ad9a843503c254 PMC10590837 37876803 10_1016_j_isci_2023_108147 S2589004223022241 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: 75N93021C00014 |
| GroupedDBID | 0R~ 53G 6I. AACTN AAEDW AAFTH AALRI AAMRU AAXUO ABMAC ADBBV ADVLN AEXQZ AFTJW AITUG ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS FDB GROUPED_DOAJ HYE M41 OK1 ROL RPM SSZ AAYWO ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP RYH AAYXX CITATION EJD NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5327-e6bb8763da00430b2643122e4639b9b08927f27ad9f6e087de25a70bd72b6433 |
| IEDL.DBID | DOA |
| ISSN | 2589-0042 |
| IngestDate | Wed Aug 27 01:31:26 EDT 2025 Thu Aug 21 18:35:56 EDT 2025 Fri Jul 11 16:41:32 EDT 2025 Thu Apr 03 06:57:35 EDT 2025 Thu Apr 24 23:04:41 EDT 2025 Sun Jul 06 05:04:35 EDT 2025 Thu Jun 26 21:45:15 EDT 2025 Sat Apr 26 15:41:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Clinical microbiology Virology |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2023 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5327-e6bb8763da00430b2643122e4639b9b08927f27ad9f6e087de25a70bd72b6433 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally Lead contact |
| ORCID | 0000-0001-5061-8296 0000-0003-2890-7256 0000-0002-1667-9287 |
| OpenAccessLink | https://doaj.org/article/bcc9e8dce069400aa6ad9a843503c254 |
| PMID | 37876803 |
| PQID | 2881713442 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bcc9e8dce069400aa6ad9a843503c254 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10590837 proquest_miscellaneous_2881713442 pubmed_primary_37876803 crossref_citationtrail_10_1016_j_isci_2023_108147 crossref_primary_10_1016_j_isci_2023_108147 nii_cinii_1872272492644395648 elsevier_sciencedirect_doi_10_1016_j_isci_2023_108147 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-11-17 |
| PublicationDateYYYYMMDD | 2023-11-17 |
| PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | iScience |
| PublicationTitleAlternate | iScience |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc Elsevier BV Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier BV – name: Elsevier |
| References | Uraki, Ito, Kiso, Yamayoshi, Iwatsuki-Horimoto, Furusawa, Sakai-Tagawa, Imai, Koga, Yamamoto (bib3) 2023; 23 Matsuyama, Nao, Shirato, Kawase, Saito, Takayama, Nagata, Sekizuka, Katoh, Kato (bib11) 2020; 117 Yue, Song, Wang, Jian, Chen, Gao, Shen, Wang, Wang, Cao (bib5) 2023; 23 Imai, Halfmann, Yamayoshi, Iwatsuki-Horimoto, Chiba, Watanabe, Nakajima, Ito, Kuroda, Kiso (bib12) 2021; 118 Uraki, Ito, Kiso, Yamayoshi, Iwatsuki-Horimoto, Sakai-Tagawa, Imai, Koga, Yamamoto, Adachi (bib10) 2023; 34 Qu, Faraone, Evans, Zheng, Carlin, Anghelina, Stevens, Fernandez, Jones, Panchal (bib2) 2023; 42 Takashita, Yamayoshi, Simon, van Bakel, Sordillo, Pekosz, Fukushi, Suzuki, Maeda, Halfmann (bib8) 2022; 387 Muramoto, Takahashi, Halfmann, Gotoh, Noda, Kawaoka (bib6) 2023; 4 Vanderheiden, Edara, Floyd, Kauffman, Mantus, Anderson, Rouphael, Edupuganti, Shi, Menachery (bib13) 2020; 131 Takashita, Morita, Ogawa, Nakamura, Fujisaki, Shirakura, Kuwahara, Kishida, Watanabe, Odagiri (bib14) 2018; 9 Chen, Li, Peng, Tian, Ji, Shi, Qian, Jiang, Liu, Li (bib1) 2023; 33 Imai, Ito, Kiso, Yamayoshi, Uraki, Fukushi, Watanabe, Suzuki, Maeda, Sakai-Tagawa (bib9) 2023; 388 Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki, Ito, Iwatsuki-Horimoto, Chiba, Halfmann, Nagai (bib7) 2022; 386 Uriu, Ito, Zahradnik, Fujita, Kosugi, Schreiber, Sato (bib4) 2023; 23 Qu (10.1016/j.isci.2023.108147_bib2) 2023; 42 Uriu (10.1016/j.isci.2023.108147_bib4) 2023; 23 Uraki (10.1016/j.isci.2023.108147_bib3) 2023; 23 Takashita (10.1016/j.isci.2023.108147_bib7) 2022; 386 Yue (10.1016/j.isci.2023.108147_bib5) 2023; 23 Vanderheiden (10.1016/j.isci.2023.108147_bib13) 2020; 131 Imai (10.1016/j.isci.2023.108147_bib9) 2023; 388 Muramoto (10.1016/j.isci.2023.108147_bib6) 2023; 4 Imai (10.1016/j.isci.2023.108147_bib12) 2021; 118 Uraki (10.1016/j.isci.2023.108147_bib10) 2023; 34 Chen (10.1016/j.isci.2023.108147_bib1) 2023; 33 Takashita (10.1016/j.isci.2023.108147_bib8) 2022; 387 Matsuyama (10.1016/j.isci.2023.108147_bib11) 2020; 117 Takashita (10.1016/j.isci.2023.108147_bib14) 2018; 9 |
| References_xml | – volume: 33 start-page: 100759 year: 2023 ident: bib1 article-title: Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection publication-title: Lancet Reg. Health. West. Pac. – volume: 9 start-page: 3026 year: 2018 ident: bib14 article-title: Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil publication-title: Front. Microbiol. – volume: 386 start-page: 995 year: 2022 end-page: 998 ident: bib7 article-title: Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant publication-title: N. Engl. J. Med. – volume: 4 start-page: e486 year: 2023 ident: bib6 article-title: Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures publication-title: Lancet. Microbe – volume: 34 start-page: 100777 year: 2023 ident: bib10 article-title: Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate publication-title: Lancet Reg. Health. West. Pac. – volume: 118 year: 2021 ident: bib12 article-title: Characterization of a new SARS-CoV-2 variant that emerged in Brazil publication-title: Proc. Natl. Acad. Sci. USA – volume: 23 start-page: 402 year: 2023 end-page: 403 ident: bib3 article-title: Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate publication-title: Lancet Infect. Dis. – volume: 388 start-page: 89 year: 2023 end-page: 91 ident: bib9 article-title: Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB publication-title: N. Engl. J. Med. – volume: 23 start-page: 278 year: 2023 end-page: 280 ident: bib5 article-title: ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5 publication-title: Lancet Infect. Dis. – volume: 42 start-page: 112443 year: 2023 ident: bib2 article-title: Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants publication-title: Cell Rep. – volume: 23 start-page: 280 year: 2023 end-page: 281 ident: bib4 article-title: Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant publication-title: Lancet Infect. Dis. – volume: 387 start-page: 468 year: 2022 end-page: 470 ident: bib8 article-title: Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants publication-title: N. Engl. J. Med. – volume: 131 start-page: e116 year: 2020 ident: bib13 article-title: Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies publication-title: Curr. Protoc. Immunol. – volume: 117 start-page: 7001 year: 2020 end-page: 7003 ident: bib11 article-title: Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells publication-title: Proc. Natl. Acad. Sci. USA – volume: 23 start-page: 402 year: 2023 ident: 10.1016/j.isci.2023.108147_bib3 article-title: Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(23)00070-1 – volume: 387 start-page: 468 year: 2022 ident: 10.1016/j.isci.2023.108147_bib8 article-title: Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2207519 – volume: 4 start-page: e486 year: 2023 ident: 10.1016/j.isci.2023.108147_bib6 article-title: Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures publication-title: Lancet. Microbe doi: 10.1016/S2666-5247(23)00100-3 – volume: 33 start-page: 100759 year: 2023 ident: 10.1016/j.isci.2023.108147_bib1 article-title: Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection publication-title: Lancet Reg. Health. West. Pac. – volume: 42 start-page: 112443 year: 2023 ident: 10.1016/j.isci.2023.108147_bib2 article-title: Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants publication-title: Cell Rep. doi: 10.1016/j.celrep.2023.112443 – volume: 9 start-page: 3026 year: 2018 ident: 10.1016/j.isci.2023.108147_bib14 article-title: Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil publication-title: Front. Microbiol. doi: 10.3389/fmicb.2018.03026 – volume: 388 start-page: 89 year: 2023 ident: 10.1016/j.isci.2023.108147_bib9 article-title: Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2214302 – volume: 131 start-page: e116 year: 2020 ident: 10.1016/j.isci.2023.108147_bib13 article-title: Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies publication-title: Curr. Protoc. Immunol. doi: 10.1002/cpim.116 – volume: 23 start-page: 278 year: 2023 ident: 10.1016/j.isci.2023.108147_bib5 article-title: ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(23)00010-5 – volume: 118 year: 2021 ident: 10.1016/j.isci.2023.108147_bib12 article-title: Characterization of a new SARS-CoV-2 variant that emerged in Brazil publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.2106535118 – volume: 34 start-page: 100777 year: 2023 ident: 10.1016/j.isci.2023.108147_bib10 article-title: Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate publication-title: Lancet Reg. Health. West. Pac. – volume: 23 start-page: 280 year: 2023 ident: 10.1016/j.isci.2023.108147_bib4 article-title: Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(23)00051-8 – volume: 117 start-page: 7001 year: 2020 ident: 10.1016/j.isci.2023.108147_bib11 article-title: Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.2002589117 – volume: 386 start-page: 995 year: 2022 ident: 10.1016/j.isci.2023.108147_bib7 article-title: Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2119407 |
| SSID | ssj0002002496 ssib044742191 |
| Score | 2.2790246 |
| Snippet | The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about... |
| SourceID | doaj pubmedcentral proquest pubmed crossref nii elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 108147 |
| SubjectTerms | Clinical microbiology Q Science Virology |
| Title | Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate |
| URI | https://dx.doi.org/10.1016/j.isci.2023.108147 https://cir.nii.ac.jp/crid/1872272492644395648 https://www.ncbi.nlm.nih.gov/pubmed/37876803 https://www.proquest.com/docview/2881713442 https://pubmed.ncbi.nlm.nih.gov/PMC10590837 https://doaj.org/article/bcc9e8dce069400aa6ad9a843503c254 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYKp14QFRRCC3Kl3qosfiS2c2QRCFWil1Jpb5ZfgSCURbBU6r_vTB6rXYTgwiWHjeOsJ589n-WZbwj5rmLJIqtjzoQLeaFFyk2CeSWZBzQjA3aYO3z5S138KX7OytlKqS-MCevlgXvDHfsQqmRiSJihyZhzysXKGfDyTAbY3eDqCz5vZTN12x2voRSeGrJk-oAuzHKdYLVwjKvjWE9lxRN1gv1rDmmjbZqXaOfz6MkVd3S-TbYGHklP-v__iXxI7Q75fdJiMQhoThNKQ7jwj7pr2Ps_LqhrI31Iw2n130TrZoGrHJ3XcIvOptMJn1QTTsdUSdoAKoGI7pKr87Or04t8qJqQh1IKnSflPcrMRdfpeXlgPJILkQrgIr7yzFRC10KDFWuVmNExidJp5qMWHprKz2Sznbdpn9BYKYf67FWQrKhLeIRr6DrVMUJ_0WeEjwa0YVAUx8IWd3YMHbu1aHSLRre90TPyY_nMfa-n8WrrKX6XZUvUwu5-AITYASH2LYRkpBy_qh1oRU8XoKvm1ZcfAgRgZHjlRguhO3nFAgBcqsJk5NsIDgtzEg9aXJvmT49WGMMxR7cQGdnrwbIcgoQVUhkmM2LWYLQ2xvU7bXPT6X7zrkC91AfvYZUv5COOFdMquf5KNhcPT-kQ-NXCH3VT6T8vtx8G |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiviral+efficacy+against+and+replicative+fitness+of+an+XBB.1.9.1+clinical+isolate&rft.jtitle=iScience&rft.au=Uraki%2C+Ryuta&rft.au=Ito%2C+Mutsumi&rft.au=Kiso%2C+Maki&rft.au=Yamayoshi%2C+Seiya&rft.date=2023-11-17&rft.pub=Elsevier&rft.eissn=2589-0042&rft.volume=26&rft.issue=11&rft_id=info:doi/10.1016%2Fj.isci.2023.108147&rft.externalDocID=PMC10590837 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2589-0042&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2589-0042&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2589-0042&client=summon |